RhumbLine Advisers’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-47,469
| Closed | -$956K | – | 4201 |
|
|
2026
Q1 | $956K | Buy |
47,469
+78
| +0.2% | +$1.26K | ﹤0.01% | 2217 |
|
|
2025
Q4 | $765K | Sell |
47,391
-5,407
| -10% | -$71.6K | ﹤0.01% | 2381 |
|
|
2025
Q3 | $643K | Sell |
52,798
-1,578
| -3% | -$21.8K | ﹤0.01% | 2523 |
|
|
2025
Q2 | $615K | Buy |
54,376
+1,458
| +3% | +$17.8K | ﹤0.01% | 2551 |
|
|
2025
Q1 | $611K | Buy |
52,918
+1,762
| +3% | +$18K | ﹤0.01% | 2444 |
|
|
2024
Q4 | $433K | Buy |
51,156
+877
| +2% | +$9.08K | ﹤0.01% | 2764 |
|
|
2024
Q3 | $582K | Sell |
50,279
-2,949
| -6% | -$37.1K | ﹤0.01% | 2598 |
|
|
2024
Q2 | $627K | Buy |
53,228
+5,908
| +12% | +$68.9K | ﹤0.01% | 2511 |
|
|
2024
Q1 | $561K | Buy |
47,320
+1,959
| +4% | +$26.1K | ﹤0.01% | 2602 |
|
|
2023
Q4 | $556K | Buy |
45,361
+3,466
| +8% | +$31.5K | ﹤0.01% | 2604 |
|
|
2023
Q3 | $403K | Buy |
41,895
+164
| +0.4% | +$1.68K | ﹤0.01% | 2736 |
|
|
2023
Q2 | $376K | Buy |
41,731
+2,909
| +7% | +$26.8K | ﹤0.01% | 2876 |
|
|
2023
Q1 | $305K | Buy |
38,822
+1,237
| +3% | +$9.23K | ﹤0.01% | 2607 |
|
|
2022
Q4 | $254K | Buy |
37,585
+72
| +0.2% | +$386 | ﹤0.01% | 2726 |
|
|
2022
Q3 | $544K | Buy |
37,513
+2,844
| +8% | +$39.8K | ﹤0.01% | 2462 |
|
|
2022
Q2 | $341K | Buy |
34,669
+12,519
| +57% | +$138K | ﹤0.01% | 2690 |
|
|
2022
Q1 | $326K | Buy |
22,150
+3,100
| +16% | +$44.5K | ﹤0.01% | 2613 |
|
|
2021
Q4 | $252K | Sell |
19,050
-11
| -0.1% | -$175 | ﹤0.01% | 2763 |
|
|
2021
Q3 | $333K | Buy |
19,061
+897
| +5% | +$18.2K | ﹤0.01% | 2725 |
|
|
2021
Q2 | $435K | Sell |
18,164
-5,013
| -22% | -$131K | ﹤0.01% | 2630 |
|
|
2021
Q1 | $595K | Buy |
23,177
+4,188
| +22% | +$110K | ﹤0.01% | 2407 |
|
|
2020
Q4 | $361K | Buy |
18,989
+3,236
| +21% | +$55.5K | ﹤0.01% | 2587 |
|
|
2020
Q3 | $198K | Sell |
15,753
-1,897
| -11% | -$23.7K | ﹤0.01% | 2692 |
|
|
2020
Q2 | $214K | Buy |
17,650
+6,923
| +65% | +$73.6K | ﹤0.01% | 2736 |
|
|
2020
Q1 | $82K | Sell |
10,727
-150
| -1% | -$2.02K | ﹤0.01% | 2811 |
|
|
2019
Q4 | $194K | Buy |
10,877
+238
| +2% | +$3.11K | ﹤0.01% | 2757 |
|
|
2019
Q3 | $123K | Sell |
10,639
-80
| -0.7% | -$1.29K | ﹤0.01% | 2853 |
|
|
2019
Q2 | $237K | Buy |
+10,719
| New | +$251K | ﹤0.01% | 2719 |
|
|
2016
Q2 | – | Sell |
-973
| Closed | -$9K | – | 3005 |
|
|
2016
Q1 | $9K | Hold |
973
| – | – | ﹤0.01% | 2988 |
|
|
2015
Q4 | $49K | Buy |
+973
| New | +$50.9K | ﹤0.01% | 3003 |
|
Other funds holding KALV
RhumbLine Advisers's KALV Position: Q2 2026 in Review
RhumbLine Advisers sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 47,469 shares — an estimated $956K sold.
RhumbLine Advisers first reported a position in KALV in Q4 2015 and held it in 30 quarters. The position peaked at $956K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- RhumbLine Advisers reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 47,469 KalVista Pharmaceuticals shares in Q2 2026, an estimated $956K.
- RhumbLine Advisers first reported a position in KalVista Pharmaceuticals in Q4 2015 and held it in 30 quarters.
- RhumbLine Advisers's KalVista Pharmaceuticals position peaked at $956K in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.